Stock Track | AxoGen Stock Plunges Despite Solid Q3 Results and Outlook

Stock Track

Nov 07, 2024

Shares of AxoGen (NASDAQ: AXGN), a leading medical technology company focused on peripheral nerve repair, plummeted by 7.96% on November 7, 2024, despite the company reporting solid third-quarter results and maintaining its full-year guidance.

AxoGen's third-quarter revenue grew by 17.9% year-over-year to $48.6 million, exceeding analysts' expectations of $47.07 million. The company attributed the robust revenue growth to improved sales productivity and commercial execution across its entire portfolio of nerve repair and protection applications.

Notably, AxoGen reported an adjusted net income of $3.1 million, or $0.07 per share, significantly higher than the adjusted net loss of $0.7 million, or $0.01 per share, in the same period last year. This also surpassed analysts' estimates of $0.01 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1100472115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100472115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100472115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100472115","market":"hk","top_or_hot":-1,"title":"Stock Track | AxoGen Stock Plunges Despite Solid Q3 Results and Outlook","media":"Stock Track","content":"<p>Shares of AxoGen (NASDAQ: AXGN), a leading medical technology company focused on peripheral nerve repair, plummeted by 7.96% on November 7, 2024, despite the company reporting solid third-quarter results and maintaining its full-year guidance.</p>\n\n<p>AxoGen's third-quarter revenue grew by 17.9% year-over-year to $48.6 million, exceeding analysts' expectations of $47.07 million. The company attributed the robust revenue growth to improved sales productivity and commercial execution across its entire portfolio of nerve repair and protection applications.</p>\n\n<p>Notably, AxoGen reported an adjusted net income of $3.1 million, or $0.07 per share, significantly higher than the adjusted net loss of $0.7 million, or $0.01 per share, in the same period last year. This also surpassed analysts' estimates of $0.01 per share.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AxoGen Stock Plunges Despite Solid Q3 Results and Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AxoGen Stock Plunges Despite Solid Q3 Results and Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-07 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of AxoGen (NASDAQ: AXGN), a leading medical technology company focused on peripheral nerve repair, plummeted by 7.96% on November 7, 2024, despite the company reporting solid third-quarter results and maintaining its full-year guidance.</p>\n\n<p>AxoGen's third-quarter revenue grew by 17.9% year-over-year to $48.6 million, exceeding analysts' expectations of $47.07 million. The company attributed the robust revenue growth to improved sales productivity and commercial execution across its entire portfolio of nerve repair and protection applications.</p>\n\n<p>Notably, AxoGen reported an adjusted net income of $3.1 million, or $0.07 per share, significantly higher than the adjusted net loss of $0.7 million, or $0.01 per share, in the same period last year. This also surpassed analysts' estimates of $0.01 per share.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXGN","symbol_name":"AxoGen Inc.","start_time":0,"source_url":"","article_id":"1100472115","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100472115","pubTimestamp":1730990136,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of AxoGen , a leading medical technology company focused on peripheral nerve repair, plummeted by 7.96% on November 7, 2024, despite the company reporting solid third-quarter results and maintaining its full-year guidance.AxoGen's third-quarter revenue grew by 17.9% year-over-year to $48.6 million, exceeding analysts' expectations of $47.07 million. The company attributed the robust revenue growth to improved sales productivity and commercial execution across its entire portfolio of nerve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXGN":"AxoGen Inc."},"translate_title":"尽管第三季度业绩和前景稳健，但AxoGen股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1},"content_text":"Shares of AxoGen (NASDAQ: AXGN), a leading medical technology company focused on peripheral nerve repair, plummeted by 7.96% on November 7, 2024, despite the company reporting solid third-quarter results and maintaining its full-year guidance.\nAxoGen's third-quarter revenue grew by 17.9% year-over-year to $48.6 million, exceeding analysts' expectations of $47.07 million. The company attributed the robust revenue growth to improved sales productivity and commercial execution across its entire portfolio of nerve repair and protection applications.\nNotably, AxoGen reported an adjusted net income of $3.1 million, or $0.07 per share, significantly higher than the adjusted net loss of $0.7 million, or $0.01 per share, in the same period last year. This also surpassed analysts' estimates of $0.01 per share.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}